Sartoretto J L, Santos R A, Scavone C, Tostes R C, Nigro D, Carvalho M H C, Cuman R K N, Fortes Z B
Department of Pharmacology, Institute of Biomedical Sciences, University of São Paulo, São Paulo, SP, Brazil.
J Pharm Pharmacol. 2007 Aug;59(8):1117-23. doi: 10.1211/jpp.59.8.0009.
Hyperglycaemia is a primary cause of vascular complications in diabetes. A hallmark of these vascular complications is endothelial cell dysfunction, which is partly due to reduced production of nitric oxide. The aim of this study was to verify the influence of improved glycaemic control with chlorpropamide on microvascular reactivity, endothelial nitric oxide synthase (e-NOS) expression, and NOS activity in neonatal streptozotocin-induced diabetic rats (n-STZ). Diabetes was induced by STZ injection into neonates Wistar rats. n-STZ diabetic rats were treated with chlorpropamide (200 mg kg(-1), 15 days, by gavage). The changes in mesenteric arteriolar and venular diameters were determined in anaesthetized control and n-STZ diabetic rats, before and after topical application of acetylcholine, bradykinin and sodium nitroprusside (SNP). We also assessed e-NOS expression (using polymerase chain reaction after reverse transcription of mRNAs into cDNAs) and NOS activity (conversion of L-arginine to citrulline) in the mesenteric vascular bed of chlorpropamide-treated n-STZ, vehicle-treated n-STZ, and control rats. In n-STZ, chlorpropamide treatment reduced high glycaemic levels, improved glucose tolerance and homoeostatic model assessment (HOMA-beta), and restored NOS activity. Impaired vasodilator responses of arterioles and venules to acetylcholine, bradykinin and SNP were partially corrected by chlorpropamide treatment in n-STZ. We concluded that improved metabolic control and restored NOS activity might be collaborating with improved microvascular reactivity found in chlorpropamide-treated n-STZ.
高血糖是糖尿病血管并发症的主要原因。这些血管并发症的一个标志是内皮细胞功能障碍,部分原因是一氧化氮生成减少。本研究的目的是验证氯磺丙脲改善血糖控制对新生链脲佐菌素诱导的糖尿病大鼠(n-STZ)微血管反应性、内皮型一氧化氮合酶(e-NOS)表达和一氧化氮合酶(NOS)活性的影响。通过向新生Wistar大鼠注射链脲佐菌素诱导糖尿病。n-STZ糖尿病大鼠经口灌胃给予氯磺丙脲(200 mg·kg⁻¹,持续15天)。在局部应用乙酰胆碱、缓激肽和硝普钠(SNP)前后,测定麻醉状态下对照大鼠和n-STZ糖尿病大鼠肠系膜小动脉和小静脉直径的变化。我们还评估了氯磺丙脲治疗的n-STZ、溶剂治疗的n-STZ和对照大鼠肠系膜血管床中e-NOS的表达(mRNA逆转录为cDNA后使用聚合酶链反应)和NOS活性(L-精氨酸向瓜氨酸的转化)。在n-STZ中,氯磺丙脲治疗降低了高血糖水平,改善了糖耐量和稳态模型评估(HOMA-β),并恢复了NOS活性。氯磺丙脲治疗部分纠正了n-STZ中小动脉和小静脉对乙酰胆碱、缓激肽和SNP的血管舒张反应受损。我们得出结论,改善代谢控制和恢复NOS活性可能与氯磺丙脲治疗的n-STZ中发现的微血管反应性改善协同作用。